This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
by Zacks Equity Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
by Zacks Equity Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.
BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.
Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
by Zacks Equity Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
by Zacks Equity Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
by Zacks Equity Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View
by Zacks Equity Research
DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss
by Zacks Equity Research
Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down
by Zacks Equity Research
For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.
Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.
Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up
by Zacks Equity Research
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
by Zacks Equity Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.